Identification of small molecules that inhibit GSK-3beta through virtual screening.
暂无分享,去创建一个
Nam Sook Kang | Chi Hyun Kim | Young Sik Cho | C. Kim | N. Kang | Myung Ae Bae | M. Bae | Y. Cho | Ikyon Kim | Gil Nam Lee | Ikyon Kim
[1] A. N. Jain,et al. Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. , 1996, Chemistry & biology.
[2] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[3] J. Westendorf,et al. Wnt signaling in osteoblasts and bone diseases. , 2004, Gene.
[4] R. Nusse,et al. Mechanisms of Wnt signaling in development. , 1998, Annual review of cell and developmental biology.
[5] Ajay N. Jain. Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities , 1996, J. Comput. Aided Mol. Des..
[6] Philip Cohen,et al. GSK3 takes centre stage more than 20 years after its discovery. , 2001 .
[7] C. Pérez,et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.
[8] H. Eldar-Finkelman,et al. The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes , 2002, Expert opinion on therapeutic targets.
[9] C. Allende,et al. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] L. Makings,et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. , 2002, Assay and drug development technologies.
[11] G. Ottmann,et al. Reactions of N-Alkyl- and N-Aryl-S-chloroisothiocarbamoyl Chlorides with Isocyanates; Synthesis of 1,2,4-Thiadiazolidine-3,5-diones† , 1966 .